Antiproliferative effects of CK2 inhibitors on cell lines of human glial tumor

• Autorzy: Pucko E. , Kazimierczuk Z. , Ostrowski R. , Stepien K. , Matyja E.
• Języki publikacji: EN

Abstrakty

EN

BACKGROUND AND AIMS: Gliomas are the most common primary brain tumours. The malignant gliomas is characterized by infiltrative growth related with poor prognosis. The therapy of astroglial tumours remains still challenging. Protein kinase (CK2) inhibitors have been suggested as promising drugs for antitumour therapy. CK2 (known as caseine kinase II) is an ubiquitous Ser/ Thr protein kinase present in both the nucleus and the cytoplasm of neoplastic cells. CK2 has been frequently found to be deregulated (mostly hyperactivated) in malignancies. It plays a role in cell survival, proliferation and can exert an anti-apoptotic role by protecting regulatory proteins from caspase-mediated degradation. The aim of this study was to evaluate the cytostatic effect of novel CK2 inhibitors on cell lines of human glial tumours. METHODS: The study was performed on human glioblastoma cell line (T98G) and cell lines derived from subependymal giant cell astrocytoma (SEGA) – a low-grade pediatric brain tumour. The tested compound included selected CK2 inhibitors: TBIAEA, DMAT, TBI and TBB. We analyzed the cell viability (MTT metabolism assay) and cell proliferation (Multisizer3 Beckman Coulter cell counter). RESULTS: The marked decrease of a total number of neoplastic cells was observed in all experimental groups, especially after 24 and 48 hours of treatment. TBIAEA appeared to be the most effective compounds that exhibit a strong anti-proliferative effect on neoplastic astroglial cells in gliomas of low and high grade malignancy in vitro. It most effectively inhibited the viability of cultured glioma cells after 24 hours at concentration 25–100 µM. CONCLUSIONS: The results show that selected CK2 inhibitors have a potent antiproliferative efficacy against human malignant glioma cells. It may offer a promising anti-tumour therapy, including treatment of glioma-derived primary brain tumours. The research was supported by the Foundation for the Development of Diagnostic and Therapy, Warsaw

• Wydawca: -
• Czasopismo: Acta Neurobiologiae Experimentalis
• Rocznik: 2015
• Tom: 75
• Numer: Supl.
• Opis fizyczny: p.S67

Twórcy

autor

Pucko E.

• Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Kazimierczuk Z.

• Department of Chemistry, Warsaw University of Life Sciences, Warsaw, Poland

autor

Ostrowski R.

• Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Stepien K.

• Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland

autor

Matyja E.

• Department of Experimental and Clinical Neuropathology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland